Chugai to build new API plant

24 April 2019

Japan’s Chugai Pharmaceutical (TYO: 4519) plans to construct a new manufacturing facility for active pharmaceutical ingredients (APIs) for clinical studies at its Fujieda Plant (Fujieda-shi, Shizuoka).

The purpose is to newly establish the manufacturing capability of middle molecule APIs for clinical studies in Chugai, as well as to enhance the supply capacity of small molecule APIs for clinical studies. This will not only accelerate the development of small and middle molecule drugs, but also reduce manufacturing costs. In addition, the number of high-potency APIs has been increasing in Chugai. Therefore, in order to ensure the safety of the environment and our researchers, advanced containment technologies will be adopted.

This investment for the new building will strengthen the process development speed and supply capacity of small and middle molecule drugs to obtain competitive advantage. Chugai, which s majority-owned by Swiss pharma giant Roche (ROG: SIX), aims to quickly deliver innovative new drugs to patients worldwide. The cost of the investment was not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK